Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with noonan syndrome

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 7, 2010, Pages 532-536

  Mehta, Parth ^a   Parker, Robert I ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Bleeding; Noonan syndrome; PAI 1; T PA

Indexed keywords

PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; PEPTIDE HYDROLASE; SERPINE1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INCIDENCE; MALE; NOONAN SYNDROME; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; SCHOOL CHILD; BLEEDING; BLOOD; METABOLISM; PHYSIOLOGY;

ADOLESCENT; ANTITHROMBIN III; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRINOLYSIS; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; NOONAN SYNDROME; PARTIAL THROMBOPLASTIN TIME; PEPTIDE HYDROLASES; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN TIME; TISSUE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 77958157544     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e0d152     Document Type: Article

References (32)

1. Noonan J, Ehmke D. Associated non cardiac malformations in children with congenital heart disease. J Pediatr. 1963;63: 468-470.
2. Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet. 2005;6:45-68.
3. Lee L, Dowhanick-Morrissette J, Katz A, et al. Chromosomal localization, genomic characterization, and mapping to the Noonan syndrome critical region of the human Deltex (DTX1) gene. Hum Genet. 2000;107:577-581.
4. Grange CS, Heid R, Lucas SB, et al. Anaesthesia in a parturient with Noonans syndrome. Can J Anaesth. 1998;45: 332-336.
5. Massarano AA, Wood A, Tait RC et al. Noonan syndrome: coagulation and clinical aspects. Acta Paediatr. 1996;85: 1181-1185.
6. Sharland M, Patton MA, Talbot S et al. Coagulation-factor deficiencies and abnormal bleeding in Noonans syndrome. Lancet 1992;339:19-21.
7. De Haan M, Kamp JJ, Briet E, et al. Noonan syndrome: partial factor XI deficiency. Am J Med Genet. 1988;29:277-282.
8. Bertola DR, Carneiro JD, DAmico EA, et al. Hematological findings in Noonan syndrome. Rev Hosp Clin Fac Med Sao Paulo. 2003;58:5-8.
9. Colman RW, Hirsch J, Marder VJ et al. Hemostasis and Thrombosis: Basic Principles & Clinical Practice. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001: 355-365.
10. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12:95-104.
11. Agren A, Wiman B, Stiller V, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost. 2006;4:201-208.
12. Santamaria A, Borrell M, Mateo J, et al. What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population. J Thromb Haemost. 2007;5:1565-1566.
13. Schleef RR, Higgins DL, Pillemer E, et al. Bleeding diathesis due to decreased function activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989;83:1747.
14. Dieval J, Nguyen G, Gross S, et al. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 1991;77:528.
15. Fay WP, Shapiro AD, Shih JL, et al. Brief Report: complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992;327:1729.
16. Mansfield MW, Strickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842-847.
17. DeMitrio V, DePergola G, Vettor R, et al. Plasma plasminogen inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women. Metabolism. 1999;48:960-964.
18. Margaglione M, Cappucci G, dAddedda M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis. Relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol. 1998;18: 562-567. (Pubitemid 28177895)
19. Kim DK, Kim JW, Kim S, et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 1997;17:3242-3247.
20. Moore JH, Smolkin ME, Lamb JM, et al. The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms. Clin Genet. 2002;62:53-59.
21. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor type-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998;79: 975-979.
22. Wiklund PG, Nilsson L, Ardnor SN, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005;36:1661-1665.
23. Saidi A, Slamia LB, Mahjoub T, et al. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI- 1/tPA levels in stroke: a case-control study. J Stroke Cerebrovasc Dis. 2007;16:153-159.
24. Haralambous E, Hibberd ML, Hermans PW, et al. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med. 2003;31:2788-2793.
25. Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet. 2006;15: R220-R226.
26. Roberts AE, Araki T, Swanson KD, et al. Germline gain-offunction mutations of SOS1 cause Noonan syndrome. Nat Genet. 2006;39:70-74.
27. Dhandapany PS, Sadayappan S, Vanniarajan A, et al. Novel mitochondrial DNA mutations implicated in Noonan syndrome. In J Cardiol. 2007;120:284-285.
28. Kietzman T, Jungermann K, Gorlach A. Regulation of the hypoxia-dependent plasminogen activator inhibitor 1 expression by MAP kinases. Thromb Haemost. 2003;89:666-673.
29. Chang H, Shyu KG, Lin S, et al. The plasminogen activator-1 gene is induced by cell adhesion through the MEK/ERK pathway. J Biomed Sci. 2003;10:738-745.
30. Yang C, Patel K, Harding P, et al. Regulation of TGF-b1/ MAPK-mediated PAI-1 gene expression by actin cytoskeleton in human mesangial cells. Exp Cell Res. 2007;313: 1240-1250.
31. Vayalil PK, Iles KE, Choi J, et al. Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1281-L1292.
32. Das F, Ghosh-Choudhury N, Venkatesan B, et al. Akt kinase targets association of CBP with SMAD 3 to regulate TGFbetainduced expression of plasminogen activator inhibitor-1. J Cell Physiol. 2008;214:513-527